| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2013 | 14-3-3ε Overexpression Contributes to Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma | Liu T.-A.; Jan Y.-J.; BOR-SHENG KO ; Liang S.-M.; Chen S.-C.; Wang J.; CHIUN HSU ; YAO-MING WU ; Liou J.-Y. | PLoS ONE | 57 | 46 | |
| 2013 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | Ying-Chun Shen ; DA-LIANG OU ; CHIUN HSU ; Lin K.-L.; Chang C.-Y.; CHING-YU LIN ; Liu S.-H.; ANN-LII CHENG | British Journal of Cancer | 140 | 135 | |
| 2010 | Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach | Ying-Chun Shen ; CHIUN HSU ; Chen L.-T.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Journal of Hepatology | 115 | 110 | |
| 2021 | Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives | Su Y.-Y.; Li C.-C.; Lin Y.-J.; CHIUN HSU | Seminars in Liver Disease | 8 | 8 | |
| 1999 | Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome | CHIUN HSU ; Lin M.-T.; JIH-LUH TANG ; HWEI-FANG TIEN ; Wang C.-H.; YAO-CHANG CHEN | Journal of the Formosan Medical Association | 5 | 6 | |
| 2011 | Antiangiogenic strategies for the treatment of hepatocellular carcinoma | CHIUN HSU ; Ying-Chun Shen ; ANN-LII CHENG | Targeted Therapies for Hepatocellular Carcinoma | 0 | 0 | |
| 2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 99 | 99 | |
| 2022 | Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma | Lee, Jan-Mou; Hung, Yi-Ping; Chou, Kai-Yuan; Lee, Cheng-Yun; Lin, Shian-Ren; Tsai, Ya-Han; Lai, Wan-Yu; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Chao, Yee | Frontiers in medicine | 0 | 0 | |
| 2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 1 | 1 | |
| 2020 | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study | Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU ; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU ; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. | The Lancet Oncology | 246 | 229 | |
| 2009 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hsu H.-C.; CHIH-HUNG HSU ; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO ; CHIUN HSU ; Hu F.-C.; YUNG-MING JENG ; Chung Y.; ANN-LII CHENG | Journal of Hepatology | 38 | 39 | |
| 2022 | AXL and MET in Hepatocellular Carcinoma: A Systematic Literature review | CHIH-HUNG HSU ; Huang Y.-H.; Lin S.-M.; CHIUN HSU | Liver Cancer | 1 | 1 | |
| 2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 39 | 40 | |
| 2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 83 | |
| 2010 | Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B | BOR-SHENG KO ; Chang T.-C.; Chen C.-H.; Liu C.-C.; Kuo C.-C.; CHIUN HSU ; Ying-Chun Shen ; Shen T.-L.; Golubovskaya V.M.; Chang C.-C.; Shyue S.-K.; Liou J.-Y. | Life Sciences | 39 | 36 | |
| 2022 | Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma | SHIH-HUNG YANG ; JEN-CHIEH LEE ; BANG-BIN CHEN ; SUNG-HSIN KUO ; CHIUN HSU ; Bai, Li-Yuan | Frontiers in Immunology | 0 | 0 | |
| 2006 | CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma | Su M.-C.; CHIUN HSU ; Kao H.-L.; YUNG-MING JENG | Cancer letters | 47 | 44 | |
| 2020 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | ANN-LII CHENG ; CHIUN HSU ; Chan S.L.; Choo S.-P.; Kudo M. | Journal of Hepatology | 188 | 185 | |
| 2000 | Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach | Liu H.-T.; CHIUN HSU ; Chen C.-L.; Chiang I.-P.; Chen L.-T.; YAO-CHANG CHEN ; ANN-LII CHENG | American Journal of Hematology | 33 | | |
| 2014 | Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study | CHIUN HSU ; Tsou H.-H.; Lin S.-J.; Wang M.-C.; MING YAO ; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; HWEI-FANG TIEN ; Liu T.-W.; PEI-JER CHEN ; ANN-LII CHENG | Hepatology | 209 | 192 | |
